KEup,KEdown
"Up Regulation, CD36","Increased, FA Influx"
"Decreased, Mitochondrial fatty acid beta-oxidation","Accumulation, Fatty acid"
"Activation, PXR/SXR","Up Regulation, CD36"
"Activation, PXR/SXR","Inhibition, FoxA2"
"Activation, PXR/SXR","Up Regulation, SCD-1"
"Accumulation, Fatty acid","Increased, Liver Steatosis"
"Increased, Triglyceride formation","Increased, Liver Steatosis"
"Up Regulation, SCD-1","Increased, Triglyceride formation"
"Increased, FA Influx","Increased, Triglyceride formation"
"Increased, FA Influx","Accumulation, Fatty acid"
"Inhibition, FoxA2","Down Regulation, CPT1A"
"Inhibition, FoxA2","Down Regulation, HMGCS2"
"Down Regulation, CPT1A","Decreased, Mitochondrial fatty acid beta-oxidation"
"Down Regulation, HMGCS2","Decreased, Ketogenesis"
"Decreased, Ketogenesis","Accumulation, Fatty acid"
"Activation, PPARα","Activation, LXR alpha"
"Inhibition, Mitochondrial fatty acid beta-oxidation","Increased, Liver Steatosis"
"Increased, De Novo FA synthesis","Increased, Liver Steatosis"
"Activation, NRF2","Activation, NR1H4"
"Activation, NR1H4","Activation, PPARα"
"Activation, NR1H4","Activation, SHP"
"Activation, SHP","Inhibition, SREBP1c"
"Decreased, DHB4/HSD17B4","Inhibition, Mitochondrial fatty acid beta-oxidation"
"Activation, LXR alpha","Increased, De Novo FA synthesis"
"N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects","Alterations, Cellular proliferation / hyperplasia"
"Activation, Long term AHR receptor driven direct and indirect gene expression changes","Formation, Hepatocellular and Bile duct tumors"
"Activation, Long term AHR receptor driven direct and indirect gene expression changes","N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects"
"Activation, Long term AHR receptor driven direct and indirect gene expression changes","Alterations, Cellular proliferation / hyperplasia"
"Activation, Long term AHR receptor driven direct and indirect gene expression changes","Changes/Inhibition, Cellular Homeostasis and Apoptosis"
"Changes/Inhibition, Cellular Homeostasis and Apoptosis","N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects"
"Alterations, Cellular proliferation / hyperplasia","Formation, Hepatocellular and Bile duct tumors"
"Hyperplasia, Hyperplasia","Promotion, Hepatocelluar carcinoma"
"N/A, Unknown","Proliferation, Cell proliferation in the absence of cytotoxicity"
"Proliferation, Cell proliferation in the absence of cytotoxicity","Hyperplasia, Hyperplasia"
"Increased, Reactive oxygen species","Increased, Oncotic Necrosis"
"Increase, cytosolic fatty acid","Increased, Liver Steatosis"
"Inhibition, Fatty Acid Beta Oxidation","Increase, cytosolic fatty acid"
"Increased, Oncotic Necrosis","N/A, Steatohepatisis"
"Increased, Liver Steatosis","Increased, Reactive oxygen species"
Peptide Oxidation,"Increase, Cytotoxicity"
"Inhibition, Pyruvate dehydrogenase kinase (PDK) enzyme","Increased, Induction of pyruvate dehydrogenase (PDH)"
"Increased, Induction of pyruvate dehydrogenase (PDH)","Increase, Oxidative metabolism"
"Increase, Cytotoxicity","Increase, hepatocellular adenomas and carcinomas"
"Increase, Oxidative metabolism",Peptide Oxidation
"Increase, cell proliferation (hepatocytes)","Increase, hepatocellular adenomas and carcinomas"
"Increase, cell proliferation (hepatocytes)","Increase, Clonal Expansion of Altered Hepatic Foci"
"Increase, Phenotypic enzyme activity","Increase, cell proliferation (hepatocytes)"
"Increase, Clonal Expansion of Altered Hepatic Foci","Increase, hepatocellular adenomas and carcinomas"
"Activation, PPARα","Increase, cell proliferation (hepatocytes)"
"Activation, PPARα","Increase, hepatocellular adenomas and carcinomas"
"Activation, PPARα","Increase, Phenotypic enzyme activity"
"Increased, extracellular matrix deposition","N/A, Liver fibrosis"
"Increased, Reactive oxygen species","Increased, extracellular matrix deposition"
Induced dysregulation of ACE2 ,Increase plasma Ang II
Increase plasma Ang II,Increased Ang II type 1 receptor (AT1R)
Increased Ang II type 1 receptor (AT1R),"Increased, Reactive oxygen species"
"Activation, AhR","Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway)"
"Activation, AhR","Suppression, VLDL secretion"
"Activation, AhR","Up Regulation, CD36"
"Activation, AhR","Up Regulation, LDLR (low density lipoprotein receptor)"
"Activation, AhR","Up Regulation, SCD-1"
"Activation, AhR","Up Regulation, CYP1A1"
"Activation, AhR","Inhibition, Mitochondrial fatty acid beta-oxidation"
"Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway)","Accumulation, Fatty acid"
"Accumulation, Triglyceride","Accumulation, Liver lipid"
"Accumulation, Fatty acid","Accumulation, Liver lipid"
"Suppression, VLDL secretion","Accumulation, Liver lipid"
"Inhibition, Mitochondrial fatty acid beta-oxidation","Accumulation, Fatty acid"
"Up Regulation, SCD-1","Accumulation, Triglyceride"
"Up Regulation, LDLR (low density lipoprotein receptor)","Increased, LDL uptake"
"Increased, LDL uptake","Accumulation, Fatty acid"
"Altered gene expression specific to CAR activation, Hepatocytes","Increase, cell proliferation (hepatocytes)"
"Activation, Constitutive androstane receptor","Altered gene expression specific to CAR activation, Hepatocytes"
"Increase, cell proliferation (hepatocytes)","Increase, Preneoplastic foci (hepatocytes)"
"Increase, Preneoplastic foci (hepatocytes)","Increase, hepatocellular adenomas and carcinomas"
"Decreased, HSD17B10 expression","Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity"
"Decreased, PPAR-alpha activation","Decreased, HSD17B10 expression"
"Decreased, PPAR-beta activation","Decreased, HSD17B10 expression"
"Decreased, PPAR-gamma activation","Decreased, HSD17B10 expression"
"Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity","Decreased, Mitochondrial fatty acid beta-oxidation"
"Formation, Pro-mutagenic DNA Adducts","Increased, Insufficient repair or mis-repair of pro-mutagenic DNA adducts"
"Formation, Pro-mutagenic DNA Adducts","Tumorigenesis, Hepatocellular carcinoma"
"Formation, Pro-mutagenic DNA Adducts","Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF)"
"Increased, Induced Mutations in Critical Genes","Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF)"
"Increased, Induced Mutations in Critical Genes","Tumorigenesis, Hepatocellular carcinoma"
"Metabolism of AFB1, Production of Reactive Electrophiles","Formation, Pro-mutagenic DNA Adducts"
"Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF)","Tumorigenesis, Hepatocellular carcinoma"
"Increased, Insufficient repair or mis-repair of pro-mutagenic DNA adducts","Increased, Induced Mutations in Critical Genes"
Leukocyte recruitment/activation,"Activation, Stellate cells"
Increased Pro-inflammatory mediators,Leukocyte recruitment/activation
Endocytotic lysosomal uptake,"Disruption, Lysosome"
"N/A, Mitochondrial dysfunction 1",Cell injury/death
"Activation, Stellate cells","Accumulation, Collagen"
Cell injury/death,Increased Pro-inflammatory mediators
"Accumulation, Collagen","N/A, Liver fibrosis"
"Disruption, Lysosome","N/A, Mitochondrial dysfunction 1"
"Activation, LXR","Up Regulation, SCD-1"
"Activation, LXR","Activation, ChREBP"
"Activation, LXR","Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)"
"Activation, LXR","Up Regulation, CD36"
"Activation, LXR","Activation, SREBF1"
"Activation, LXR","Inhibition, PPAR alpha"
"Activation, LXR","Up Regulation, FAS"
"Activation, ChREBP","Increased, De Novo FA synthesis"
peroxisome proliferator activated receptor promoter demethylation,"Activation, SREBF1"
peroxisome proliferator activated receptor promoter demethylation,"Increased, FA Influx"
"Accumulation, Fatty acid","Increased, Triglyceride formation"
"Suppression, Constitutive androstane receptor, NR1l3","Activation, LXR"
"Suppression, Constitutive androstane receptor, NR1l3",peroxisome proliferator activated receptor promoter demethylation
"Activation, SREBF1","Up Regulation, SCD-1"
"Increased, De Novo FA synthesis","Accumulation, Fatty acid"
"Up Regulation, FAS","Increased, De Novo FA synthesis"
"Inhibition, PPAR alpha","Inhibition, Mitochondrial fatty acid beta-oxidation"
"Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)","Increased, De Novo FA synthesis"
"Increase, Cytotoxicity (hepatocytes)","Increase, Regenerative cell proliferation (hepatocytes)"
"Increase, Regenerative cell proliferation (hepatocytes)","Increase, Preneoplastic foci (hepatocytes)"
"Inhibition, Phospholipase A","Disturbance, Lysosomal function"
"Inhibition, Phospholipase A","Damage, Lipid bilayer"
"Inhibition, Phospholipase A","Injury, Mitochondria"
"Damage, Lipid bilayer","Occurrence, Cytoplasmic vacuolization (Bile duct cell)"
"Damage, Lipid bilayer","Occurrence, Cytoplasmic vacuolization (hepatocyte)"
"Damage, Lipid bilayer","Occurrence, Cytoplasmic vacuolization (kupffer cell)"
"Damage, Lipid bilayer","Occurrence, Ballooning degeneration (hepatocyte)"
"Disturbance, Lysosomal function","Occurrence, Ballooning degeneration (hepatocyte)"
"Disturbance, Lysosomal function","Occurrence, Cytoplasmic vacuolization (kupffer cell)"
"Disturbance, Lysosomal function","Occurrence, Cytoplasmic vacuolization (Bile duct cell)"
"Disturbance, Lysosomal function","Occurrence, Cytoplasmic vacuolization (hepatocyte)"
"Injury, Mitochondria","Occurrence, Cytoplasmic vacuolization (kupffer cell)"
"Injury, Mitochondria","Occurrence, Cytoplasmic vacuolization (hepatocyte)"
"Injury, Mitochondria","Occurrence, Ballooning degeneration (hepatocyte)"
"Injury, Mitochondria","Occurrence, Cytoplasmic vacuolization (Bile duct cell)"
"Occurrence, Cytoplasmic vacuolization (hepatocyte)","Induction, Microvesicular fat"
"Occurrence, Cytoplasmic vacuolization (hepatocyte)","Formation, Mallory body"
"Occurrence, Ballooning degeneration (hepatocyte)","Induction, Microvesicular fat"
"Occurrence, Ballooning degeneration (hepatocyte)","Formation, Mallory body"
"Occurrence, Cytoplasmic vacuolization (Bile duct cell)","Induction, Microvesicular fat"
"Occurrence, Cytoplasmic vacuolization (Bile duct cell)","Formation, Mallory body"
"Occurrence, Cytoplasmic vacuolization (kupffer cell)","Induction, Microvesicular fat"
"Occurrence, Cytoplasmic vacuolization (kupffer cell)","Formation, Mallory body"
"Induction, Microvesicular fat","Formation, Liver fibrosis"
"Formation, Mallory body","Formation, Liver fibrosis"
"Inhibition, IKK complex","Inhibition, Nuclear factor kappa B (NF-kB)"
"Activation, Caspase 8 pathway",Cell injury/death
Necrotic Tissue,Liver Injury
"Activation, Tissue resident cells (Kuppfer cells)","Increase, proinflammatory mediators (TNFalpha)"
"Inhibition, Nuclear factor kappa B (NF-kB)","Activation, Caspase 8 pathway"
Cell injury/death,"Activation, Tissue resident cells (Kuppfer cells)"
Cell injury/death,Necrotic Tissue
Increase in inflammation,Immune mediated hepatitis
benzoquinone imine and acylglucuronide metabolites,Immune cell activation
benzoquinone imine and acylglucuronide metabolites,Mitochondrial dysfunction
Activation of ER stress,Apoptotic cell death
Mitochondrial dysfunction,Apoptotic cell death
Mitochondrial dysfunction,Activation of ER stress
Apoptotic cell death,Increase in inflammation
Immune cell activation,IFNγ signaling
IFNγ signaling,Increase in inflammation
NFE2/Nrf2 repression,"Reduced, FXR activity"
"Reduced, FXR activity","Reduced, SHP activity"
"Reduced, SHP activity","Activated, LXR"
"Activated, LXR","Reduced, PPARalpha"
"Reduced, PPARalpha","Reduced, HSD17B4 activity"
"Reduced, HSD17B4 activity","Reduced, fatty acid beta oxidation"
"Reduced, fatty acid beta oxidation","Increased, steatosis"
"Activation, PARP1","N/A, Mitochondrial dysfunction 1"
"Activation, Glucocorticoid Receptor","Decrease, Acyl-CoA dehydrogenases"
"Decrease, Acyl-CoA dehydrogenases","Decreased, Mitochondrial Fatty Acid Beta Oxidation"
"Accumulation, Triglyceride","Increased, Liver Steatosis"
"Decreased, Mitochondrial Fatty Acid Beta Oxidation","Accumulation, Triglyceride"
"Increase, Mitochondrial complex III antagonism",Decrease in mitochondrial oxidative phosphorylation
Mitochondrial Complex IV inhibition,Decrease in mitochondrial oxidative phosphorylation
Mitochondrial Complex V inhibition,Decrease in mitochondrial oxidative phosphorylation
"Inhibition, NADH-ubiquinone oxidoreductase  (complex I)",Decrease in mitochondrial oxidative phosphorylation
"Binding of inhibitor, NADH-ubiquinone oxidoreductase (complex I)","Inhibition, NADH-ubiquinone oxidoreductase  (complex I)"
Decrease in mitochondrial oxidative phosphorylation,"N/A, Mitochondrial dysfunction 1"
Increased reactive oxygen species (in the mitochondria),"N/A, Mitochondrial dysfunction 1"
Binding of inhibitor to mitochondrial complex III,"Increase, Mitochondrial complex III antagonism"
Binding of inhibitor to mitochondrial complex IV,Mitochondrial Complex IV inhibition
Binding of inhibitor to mitochondrial complex V,Mitochondrial Complex V inhibition
"N/A, Mitochondrial dysfunction 1",Increased reactive oxygen species (in the mitochondria)
"N/A, Mitochondrial dysfunction 1","Impaired, Proteostasis"
"Impaired, Proteostasis",Cell injury/death
Tissue resident cell activation,Increased Pro-inflammatory mediators
Increased Pro-inflammatory mediators,"Activation, Stellate cells"
"Alkylation, Protein",Cell injury/death
Cell injury/death,Tissue resident cell activation
Cell injury/death,"Activation, Stellate cells"
Activation of Cyp2E1,Oxidative Stress 
Activation of Cyp2E1,Hepatocytotoxicity
Oxidative Stress ,Hepatocytotoxicity
Oxidative Stress ,Liver Cancer
Hepatocytotoxicity,"Induction, persistent proliferation/sustained proliferation"
Hepatocytotoxicity,Liver Cancer
"Induction, persistent proliferation/sustained proliferation",Liver Cancer
"Increase, FA Influx","Accumulation, Triglyceride"
"Activation, FAS","Synthesis, De Novo FA"
"Activation, LXR","Activation, SCD-1"
"Activation, LXR","Activation, FAS"
"Activation, LXR","Activation, SREBP-1c"
"Activation, SCD-1","Synthesis, De Novo FA"
"Activation, SREBP-1c","Synthesis, De Novo FA"
"Up Regulation, CD36","Increase, FA Influx"
"Activation, ChREBP","Synthesis, De Novo FA"
"Synthesis, De Novo FA","Accumulation, Triglyceride"
peroxisome proliferator activated receptor promoter demethylation,"Up Regulation, CD36"
"Accumulation, Triglyceride","Damaging, Mitochondria"
"Activation, SREBF1","Increased, Liver Steatosis"
"Activation, AKT2","Activation, SREBF1"
systemic inflammation leading to hepatic steatosis,"Activation, AKT2"
"Inhibition, Bile Salt Export Pump (ABCB11)","Bile accumulation, Pathological condition"
"Increase, Inflammation","Cholestasis, Pathology"
Peptide Oxidation,"Cholestasis, Pathology"
"Bile accumulation, Pathological condition","Production, Reactive oxygen species"
"Bile accumulation, Pathological condition","Release, Cytokine"
"Bile accumulation, Pathological condition","Activation of specific nuclear receptors, Transcriptional change"
"Production, Reactive oxygen species",Peptide Oxidation
"Activation of specific nuclear receptors, Transcriptional change","Cholestasis, Pathology"
"Release, Cytokine","Increase, Inflammation"
"Up Regulation, SREBF2","Up Regulation, Unsaturated fatty acid"
"Up Regulation, Unsaturated fatty acid",Perturbation of cholesterol
"Down Regulation, GSS and GSTs gene",Glutathione homeostasis
"Down Regulation, GSS and GSTs gene",Glutathione synthesis
Glutathione synthesis,"Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene"
"Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene",Perturbation of cholesterol
Perturbation of cholesterol,Hepatotoxicity
Glutathione homeostasis,Hepatotoxicity
"Activation, Androgen receptor","Increase, cell proliferation (hepatocytes)"
Unfolded Protein Response,Apoptosis
Inhibition of N-linked glycosylation,Accumulation of misfolded proteins
Apoptosis,Activation of hepatic stellate cells
Apoptosis,Liver Injury
Accumulation of misfolded proteins,Unfolded Protein Response
Activation of hepatic stellate cells,Liver Injury
